The long term objective of this competing renewal grant application is to develop novel prodrug strategies to improve corneal permeability of topically applied antimicrobial agents employed in the treatment of both bacterial and viral corneal stromal and epithelial keratitis. In this grant proposal we aim to characterize the ascorbate carrier systems expressed on the corneal membrane. We also propose to synthesize amino acid, peptide and ascorbate ester prodrugs of erythromycin, levofloxacin and ofloxacin and ascorbate ester prodrugs of ACV, targeted towards the respective transporters expressed on the corneal membrane, and to evaluate their ability to circumvent P-gp and MRP mediated efflux.
The specific aims of this renewal application are a) To synthesize derivatives of erythromycin, levofloxacin and ofloxacin targeting amino acid (phenylalanine and glutamate prodrugs), peptide (valine, valine-valine and glycine-valine prodrugs) and ascorbate (ascorbic acid prodrugs) transporters expressed on the cornea and to evaluate these conjugates with respect to their b) physiochemical properties and cytotoxicity;c) bio- reversion in ocular fluids and cell homogenates, d) uptake, transport and simultaneous bioreversion across isolated rabbit cornea, and human and rabbit primary corneal epithelial cell cultures, e) affinity for P-gp and MRP efflux pumps, f) in vitro antibacterial efficacy and g) in vivo antibacterial efficacy against bacterial keratitis in the rabbit model. In vitro and in vivo studies will be conducted by Dr. William Suling at the Southern Research Institute, Birmingham, AL and by Dr. James Hill at the LSU Eye Center, New Orleans, LA, respectively. Uptake and transport of erythromycin, levofloxacin and ofloxacin prodrugs will be studied across isolated rabbit cornea, human and rabbit primary corneal epithelial cell cultures (rPCEC), alone, in combination and in the presence of topically applied anti-inflammatory steroids (prednisolone, prednisone and 6-alpha-methylprednisolone). We propose to synthesize ascorbate prodrug of ACV study transport and simultaneous bio-reversion across isolated rabbit corneas, and human and rabbit primary corneal epithelial cell cultures;antiviral efficacy against in vitro viral screens of HSV-1, HSV-2, CMV, VZV and EBV and in vivo antiviral efficacy against HSV-1 (McKrae strain) induced acute epithelial and stromal keratitis in the rabbit model. In vitro and in vivo studies will be conducted by Dr. Sam Ananthan and Dr. Earl Kern under NIAID funded research contract and by Dr. James Hill. n vivo ocular bioavailability of erythromycin, levofloxacin, ofloxacin and ACV and their prodrugs will be examined following topical application (alone, in combination or in the presence of prednisolone, prednisone and 6-alpha-methylprednisolone as inhibitors of corneal efflux pumps) in both anesthetized and conscious rabbit models by employing ocular microdialysis technique.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY009171-16
Application #
7751254
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Shen, Grace L
Project Start
1994-11-01
Project End
2011-12-31
Budget Start
2010-01-01
Budget End
2011-12-31
Support Year
16
Fiscal Year
2010
Total Cost
$297,615
Indirect Cost
Name
University of Missouri Kansas City
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
010989619
City
Kansas City
State
MO
Country
United States
Zip Code
64110
Mandal, Abhirup; Bisht, Rohit; Rupenthal, Ilva D et al. (2017) Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J Control Release 248:96-116
Joseph, Mary; Trinh, Hoang M; Cholkar, Kishore et al. (2017) Recent perspectives on the delivery of biologics to back of the eye. Expert Opin Drug Deliv 14:631-645
Agrahari, Vibhuti; Li, Guorong; Agrahari, Vivek et al. (2017) Pentablock copolymer dexamethasone nanoformulations elevate MYOC: in vitro liberation, activity and safety in human trabecular meshwork cells. Nanomedicine (Lond) 12:1911-1926
Agrahari, Vibhuti; Agrahari, Vivek; Hung, Wei-Ting et al. (2016) Composite Nanoformulation Therapeutics for Long-Term Ocular Delivery of Macromolecules. Mol Pharm 13:2912-22
Patel, Sulabh P; Vaishya, Ravi; Patel, Ashaben et al. (2016) Optimization of novel pentablock copolymer based composite formulation for sustained delivery of peptide/protein in the treatment of ocular diseases. J Microencapsul 33:103-13
Agrahari, Vibhuti; Mandal, Abhirup; Agrahari, Vivek et al. (2016) A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res 6:735-754
Agrahari, Vibhuti; Agrahari, Vivek; Mitra, Ashim K (2016) Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities. Ther Deliv 7:257-78
Cholkar, Kishore; Gilger, Brian C; Mitra, Ashim K (2016) Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). Int J Pharm 498:326-34
Patel, Sulabh P; Vaishya, Ravi; Pal, Dhananjay et al. (2015) Novel pentablock copolymer-based nanoparticulate systems for sustained protein delivery. AAPS PharmSciTech 16:327-43
Cholkar, Kishore; Gunda, Sriram; Earla, Ravinder et al. (2015) Nanomicellar Topical Aqueous Drop Formulation of Rapamycin for Back-of-the-Eye Delivery. AAPS PharmSciTech 16:610-22

Showing the most recent 10 out of 160 publications